Expert Opinion: Recent Approval of Cladribine in EU

SPECIAL REPORT: Expert Opinion on New MS Drug Approval

SPECIAL REPORT: Expert Opinion on New MS Drug Approval
RestartResume
Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis.
  • Overview

    Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. This short discussion reviews the path to approval, the importance of the first approval for an oral short-course treatment option, and the future holds for this drug.

    To learn more about current and future treatment options for MS patients,click here

  • Faculty

    Professor Ralf Gold
    Global Neurology Academy Steering Committee Member
    Professor and Department Chair
    St Josef Spital; Ruhr University Bochum
    Bochum, Germany

Facebook Comments

Register

We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free